Personalized prediction for a 42 year old woman who takes Hyrimoz (an AI-powered real world drug study)

Summary:

This is a personalized prediction of potential side effects and undetected conditions for up to one year, if you would have adverse effects. The study is created by eHealthMe based on data from the FDA.

What are the drugs?

Hyrimoz has active ingredients of adalimumab-adaz. eHealthMe is studying from 4,634 Hyrimoz users. Check the latest studies of Hyrimoz.

What are the conditions?

Ankylosing spondylitis (type of arthritis affecting the spine) is found to be associated with 809 drugs and 999 conditions by eHealthMe. Check the latest studies of Ankylosing spondylitis.

What are the symtoms?

Chest pain is found to be associated with 3,503 drugs and 4,838 conditions by eHealthMe. Check the latest studies of Chest pain.

Potential side effects:

Ankylosing spondylitis

8.62% for females aged 42 (±5) who have ankylosing spondylitis

Back pain

7.5% for females aged 42 (±5) who have ankylosing spondylitis

Chest pain

100.0% for females aged 42 (±5) who take hyrimoz and have chest pain
100.0% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

Drug ineffective

9.47% for females aged 42 (±5) who have ankylosing spondylitis
6.17% for females aged 42 (±5) who take hyrimoz

Fatigue

10.53% for females aged 42 (±5) who have ankylosing spondylitis
6.58% for females aged 42 (±5) who take hyrimoz

Headache

8.06% for females aged 42 (±5) who have ankylosing spondylitis
5.95% for females aged 42 (±5) who take hyrimoz

Injection site erythema

5.77% for females aged 42 (±5) who have ankylosing spondylitis

Injection site pain

8.97% for females aged 42 (±5) who have ankylosing spondylitis

Joint pain

10.94% for females aged 42 (±5) who have ankylosing spondylitis

Malaise

5.52% for females aged 42 (±5) who have ankylosing spondylitis

Musculoskeletal stiffness

5.63% for females aged 42 (±5) who have ankylosing spondylitis

Nausea

6.54% for females aged 42 (±5) who take hyrimoz
5.95% for females aged 42 (±5) who have ankylosing spondylitis

Pain

11.71% for females aged 42 (±5) who have ankylosing spondylitis

Pain in extremity

5.31% for females aged 42 (±5) who have ankylosing spondylitis

Rashes

5.07% for females aged 42 (±5) who have ankylosing spondylitis

Potential co-existing conditions:

Asthma

5.03% for females aged 42 (±5) who take hyrimoz and have chest pain

Crohn's disease

11.0% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

Pain

9.39% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

Psoriasis

8.09% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

Psoriatic arthropathy

13.59% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

Rheumatoid arthritis

12.62% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

Stress and anxiety

5.83% for females aged 42 (±5) who have chest pain with ankylosing spondylitis

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used, and more. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

Related publications that referenced our studies

Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .
Hung YM, Cheng CC, Wann SR, Lin SL, "Ankylosing spondylitis associated with pulmonary arterial hypertension", Internal Medicine, 2016 Jan .

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.